Colorectal cancer (CRC) is one of the deadliest cancers worldwide. It’s more prevalent in men and its incidence increasing with age. Secondary prevention is based on fecal occult blood test (FOBT) starting at 50 years of age, but it is not specific for CRC and its sensitivity ranging from 79% to 88%. The overall aim of this study was to identify new potentially peptide/protein biomarkers for the non-invasive early diagnosis of colorectal carcinoma. Faecal and salivary samples of healthy controls, Crohn Disease (CD) and Ulcerative Colitis (UC) patients were analyzed by LTQ-Orbitrap LC-MS/MS. The main finding of this study is the discovery that the Basic salivary proline-rich protein 1 (PRB1) and its derived peptides are enriched in feces of CD patients. Moreover, we demonstrated their pro-proliferative effect on both Human CRC cell lines and Rat colonic Mesenchymal Stem Cells. In future, Human Intestinal Mesenchymal Stem Cells will be used as a human in vitro model to ascertain not only the biological effects of the already identified salivary protein but also of new emerging ones.
Il cancro al colon-retto è uno dei tumori più mortali al mondo. È prevalente negli uomini e la sua incidenza aumenta con l’età. Lo screening a partire dai 50 anni di età viene effettuato attraverso il test del sangue occulto fecale, test non specifico per il cancro al colon-retto e con una sensibilità variabile (79%-88%). Lo scopo del presente studio è di identificare nuovi potenziali biomarcatori peptidici e/o proteici per la diagnosi precoce e non-invasiva del cancro al colon-retto. Campioni salivari e fecali di soggetti sani, pazienti affetti da morbo di Crohn, rettocolite ulcerosa e cancro al colon-retto sono stati analizzati mediante spettrometria di massa LTQ-Orbitrap LC-MS. Questo studio ha permesso di identificare la proteina salivare PRB1 e i suoi peptidi in campioni fecali di pazienti affetti da morbo di Crohn. È stato inoltre dimostrato l’effetto pro-proliferativo dei peptidi salivari sia in cellule di adenocarcinoma del colon-retto umane sia su cellule staminali mesenchimali isolate dal colon di ratto. In futuro, dovranno essere confermati gli effetti biologici di questi peptidi salivari e di potenziali nuovi biomarcatori su cellule staminali mesenchimali umane isolate da intestino.
RESEARCH OF NEW FAECAL AND SALIVARY BIOMARKERS FOR THE NON-INVASIVE DIAGNOSIS OF COLORECTAL CARCINOMA / Contran, Nicole. - (2023 Mar 06).
RESEARCH OF NEW FAECAL AND SALIVARY BIOMARKERS FOR THE NON-INVASIVE DIAGNOSIS OF COLORECTAL CARCINOMA
CONTRAN, NICOLE
2023
Abstract
Colorectal cancer (CRC) is one of the deadliest cancers worldwide. It’s more prevalent in men and its incidence increasing with age. Secondary prevention is based on fecal occult blood test (FOBT) starting at 50 years of age, but it is not specific for CRC and its sensitivity ranging from 79% to 88%. The overall aim of this study was to identify new potentially peptide/protein biomarkers for the non-invasive early diagnosis of colorectal carcinoma. Faecal and salivary samples of healthy controls, Crohn Disease (CD) and Ulcerative Colitis (UC) patients were analyzed by LTQ-Orbitrap LC-MS/MS. The main finding of this study is the discovery that the Basic salivary proline-rich protein 1 (PRB1) and its derived peptides are enriched in feces of CD patients. Moreover, we demonstrated their pro-proliferative effect on both Human CRC cell lines and Rat colonic Mesenchymal Stem Cells. In future, Human Intestinal Mesenchymal Stem Cells will be used as a human in vitro model to ascertain not only the biological effects of the already identified salivary protein but also of new emerging ones.File | Dimensione | Formato | |
---|---|---|---|
Tesi definitiva_Nicole Contran_rev.pdf
embargo fino al 05/03/2026
Descrizione: RESEARCH OF NEW FAECAL AND SALIVARY BIOMARKERS FOR THE NON-INVASIVE DIAGNOSIS OF COLORECTAL CARCINOMA
Tipologia:
Tesi di dottorato
Dimensione
3.99 MB
Formato
Adobe PDF
|
3.99 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.